Manganese sulfate - Medesis Pharma
Alternative Names: NanoManganese®; NP-02; NP02 - NanoManganese®Latest Information Update: 07 Nov 2023
At a glance
- Originator Medesis Pharma
- Class Heavy metals
- Mechanism of Action Superoxide dismutase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID 2019 infections
- Preclinical Radiation injuries; SARS-CoV-2 acute respiratory disease
Most Recent Events
- 26 Oct 2023 Medesis Pharma terminates a phase II trial in COVID-2019 infections in Brazil (PO) because of the insufficient recruitment in the trial due to lower COVID cases (NCT05451654)
- 04 Feb 2022 Phase-II clinical trials in COVID-2019 infections in Brazil (PO) (NCT05451654)
- 06 Apr 2021 Medesis Pharma plans to request for Temporary Authorization for Use (ATU) for SARS-COV-2 acute respiratory disease in France in Q4 of 2021